Patents Assigned to SINOMAB BIOSCIENCE LIMITED
  • Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor
    Patent number: 11180475
    Abstract: Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 23, 2021
    Assignee: SinoMab BioScience Limited
    Inventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu
  • Cell lines expressing surface bound anti-idiotype antibodies against anti-CD22 antibodies and uses thereof
    Patent number: 10613099
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 7, 2020
    Assignee: Sinomab Bioscience Limited
    Inventor: Shui-on Leung
  • CELL LINES EXPRESSING SURFACE BOUND ANTI-IDIOTYPE ANTIBODIES AGAINST ANTI-CD22 ANTIBODIES AND USES THEREOF
    Publication number: 20160363597
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 15, 2016
    Applicant: SINOMAB BIOSCIENCE LIMITED
    Inventor: Shui-on LEUNG
  • Anti-CD22 anti-idiotypic antibodies and uses thereof
    Patent number: 9371396
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies.
    Type: Grant
    Filed: June 16, 2013
    Date of Patent: June 21, 2016
    Assignee: Sinomab Bioscience Limited
    Inventor: Shui-on Leung
  • ANTI-CD22 ANTI-IDIOTYPIC ANTIBODIES AND USES THEREOF
    Publication number: 20150175711
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies.
    Type: Application
    Filed: June 16, 2013
    Publication date: June 25, 2015
    Applicant: SINOMAB BIOSCIENCE LIMITED
    Inventor: Shui-on Leung